Related Experiment Videos
Intravitreal bevacizumab for myopic choroidal neovascularization
Florian Rensch1, Ulrich H M Spandau, Frank Schlichtenbrede
1Department of Ophthalmology, Medical Faculty Mannheim of the Ruprecht-Karls-University Heidelberg, Mannheim, Germany.
Background And Objective:
To evaluate the effect of intravitreal bevacizumab on visual acuity in patients with myopic choroidal neovascularization.
Patients And Methods:
The retrospective case series study included 13 patients with myopic choroidal neovascularization who received three intravitreal injections of 1.5 mg of bevacizumab.
Results:
At 1, 3, and 6 months after the first injection, mean visual acuity improved significantly from 0.63 +/- 0.41 logarithm of the minimum angle of resolution units (LogMAR) to 0.39 +/- 0.22 (P< .001), 0.47 +/- 0.49 (P= .002), and 0.52 +/- 0.49 LogMAR (P = 0.009), respectively. The increase in visual acuity was correlated with a significant decrease in central retinal thickness (P = .003) as measured by optical coherence tomography. Mean intraocular pressure did not change significantly (P> .05) during follow-up.
Conclusion:
Intravitreal injections of bevacizumab may be a therapeutic option for exudative myopic macular degeneration.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Diabetic Retinopathy
Glaucoma: Overview